G

Galectin Therapeutics
D

GALT

1.36000
USD
0.03
(2.26%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
86,076,556
أصول ذات صلة
E
EBS
-0.34500
(-5.23%)
6.25000 USD
E
EXAS
-0.460
(-0.85%)
53.530 USD
H
HAE
-1.210
(-1.70%)
70.100 USD
I
INO
-0.07000
(-3.38%)
2.00000 USD
NBIX
NBIX
-0.670
(-0.54%)
124.400 USD
S
SRPT
-1.080
(-2.90%)
36.170 USD
VRTX
VRTX
-4.36
(-0.95%)
455.70 USD
المزيد
الأخبار المقالات

العنوان: Galectin Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.